Bio-Rad Laboratories Past Earnings Performance
Past criteria checks 0/6
Bio-Rad Laboratories's earnings have been declining at an average annual rate of -28.9%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 5% per year.
Key information
-28.9%
Earnings growth rate
-28.9%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 5.0% |
| Return on equity | -7.3% |
| Net Margin | -23.9% |
| Next Earnings Update | 07 May 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Bio-Rad Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2,671 | -637 | 824 | 241 |
| 30 Sep 23 | 2,720 | -159 | 827 | 244 |
| 30 Jun 23 | 2,769 | -428 | 838 | 268 |
| 31 Mar 23 | 2,779 | -191 | 844 | 268 |
| 31 Dec 22 | 2,802 | -3,628 | 825 | 257 |
| 30 Sep 22 | 2,805 | -6,021 | 808 | 236 |
| 30 Jun 22 | 2,871 | -1,930 | 814 | 234 |
| 31 Mar 22 | 2,896 | -91 | 821 | 233 |
| 31 Dec 21 | 2,923 | 4,254 | 851 | 247 |
| 30 Sep 21 | 2,980 | 6,659 | 875 | 268 |
| 30 Jun 21 | 2,880 | 4,045 | 857 | 263 |
| 31 Mar 21 | 2,701 | 4,098 | 832 | 251 |
| 31 Dec 20 | 2,546 | 3,814 | 799 | 218 |
| 30 Sep 20 | 2,380 | 3,521 | 784 | 212 |
| 30 Jun 20 | 2,294 | 1,947 | 786 | 200 |
| 31 Mar 20 | 2,329 | 1,579 | 798 | 198 |
| 31 Dec 19 | 2,312 | 1,759 | 825 | 203 |
| 30 Sep 19 | 2,304 | 377 | 817 | 198 |
| 30 Jun 19 | 2,289 | 905 | 822 | 200 |
| 31 Mar 19 | 2,292 | 574 | 831 | 197 |
| 31 Dec 18 | 2,289 | 366 | 835 | 199 |
| 30 Sep 18 | 2,294 | 1,277 | 835 | 199 |
| 30 Jun 18 | 2,283 | 1,030 | 827 | 212 |
| 31 Mar 18 | 2,212 | 767 | 827 | 227 |
| 31 Dec 17 | 2,160 | 122 | 803 | 235 |
| 30 Sep 17 | 2,110 | 17 | 819 | 232 |
| 30 Jun 17 | 2,085 | 13 | 814 | 220 |
| 31 Mar 17 | 2,097 | 26 | 798 | 207 |
| 31 Dec 16 | 2,068 | 26 | 786 | 206 |
| 30 Sep 16 | 2,067 | 98 | 776 | 204 |
| 30 Jun 16 | 2,028 | 97 | 772 | 198 |
| 31 Mar 16 | 2,018 | 108 | 768 | 194 |
| 31 Dec 15 | 2,019 | 109 | 762 | 193 |
| 30 Sep 15 | 2,047 | 103 | 769 | 193 |
| 30 Jun 15 | 2,108 | 97 | 787 | 203 |
| 31 Mar 15 | 2,139 | 100 | 796 | 212 |
| 31 Dec 14 | 2,175 | 89 | 810 | 220 |
| 30 Sep 14 | 2,179 | 80 | 828 | 217 |
| 30 Jun 14 | 2,154 | 61 | 825 | 217 |
| 31 Mar 14 | 2,142 | 64 | 820 | 213 |
| 31 Dec 13 | 2,133 | 78 | 804 | 211 |
| 30 Sep 13 | 2,104 | 91 | 774 | 214 |
| 30 Jun 13 | 2,098 | 141 | 739 | 206 |
Quality Earnings: BIO.B is currently unprofitable.
Growing Profit Margin: BIO.B is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BIO.B is unprofitable, and losses have increased over the past 5 years at a rate of 28.9% per year.
Accelerating Growth: Unable to compare BIO.B's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIO.B is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-6.6%).
Return on Equity
High ROE: BIO.B has a negative Return on Equity (-7.29%), as it is currently unprofitable.